However, the gene expression and the pharmacokinetic studies with highly specific HPLC-MS excluded this hypothesis, as no difference in expression of the MDR1 gene was observed and tumour drug levels were comparable to or even slightly higher in the resistant than the sensitive model. Here, ABCB1 is linked to neoplasm.